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The potential of combined immunotherapy and antiangiogenesis for the synergistic 
treatment of advanced NSCLC. 
 
Over the past few years, there have been considerable advances in the treatments 
available to patients with metastatic or locally advanced NSCLC, particularly those who 
have progressed during first-line treatment. Some of the treatment options available to 
patients are discussed here, with a focus on checkpoint inhibitor immunotherapies 
(nivolumab and pembrolizumab) and antiangiogenic agents (bevacizumab, ramucirumab, 
and nintedanib). It is hypothesized that combining immunotherapy with antiangiogenic 
treatment may have a synergistic effect and enhance the efficacy of both treatments. In 
this review, we explore the theory and potential of this novel treatment option for patients 
with advanced NSCLC. We discuss the growing body of evidence that proangiogenic 
factors can modulate the immune response (both by reducing T-cell infiltration into the 
tumor microenvironment and through systemic effects on immune-regulatory cell function), 
and we examine the preclinical evidence for combining these treatments. Potential 
challenges are also considered, and we review the preliminary evidence of clinical efficacy 
and safety with this novel combination in a variety of solid tumor types. 
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Introduction 
Over the past decade, there have been considerable advances in the treatment of 
metastatic or locally advanced NSCLC, particularly in the treatment of patients 
experiencing progression during or after first-line treatment. First-line treatment for patients 
with advanced NSCLC without targetable tumor-specific mutations involves the 
administration of platinum-based chemotherapy doublets with or without bevacizumab or 
necitumumab. Several targeted therapies are also approved for use by the European 
Medicines Agency (EMA) and/or the U.S. Food and Drug Administration (FDA) for the first-
line treatment of patients with advanced NSCLC with known oncogene addiction. Gefitinib, 
erlotinib, and afatinib, which are EGFR-specific tyrosine kinase inhibitors (TKIs), are FDA 
and EMA approved in patients with EGFR activating mutations. Crizotinib, which targets 
the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase, is also FDA and EMA 
approved for ALK-positive patients and approved by the FDA for use in patients 
with ROS1 gene alterations. 
Despite improvements in first-line therapy, all patients with advanced disease will 
eventually require further treatment. Recently, a number of agents developed for use in 
patients without oncogene addiction who progress during or after chemotherapy have 
been approved by the EMA and/or the FDA. Largely, these fall into one of two categories: 
antiangiogenic agents and checkpoint inhibitor immunotherapies. Antiangiogenic agents 
include nintedanib (EMA approved), which is a triple angiokinase inhibitor for use in 
patients with NSCLC of the adenocarcinoma histologic type, and ramucirumab (FDA and 
EMA approved), which is a humanized monoclonal antibody targeting vascular endothelial 
growth factor receptor-2 (VEGFR2). Checkpoint inhibitor immunotherapies that are 
available for the treatment of NSCLC include nivolumab and pembrolizumab, which are 
monoclonal antibodies that inhibit the programmed cell death protein 1 (PD-1) receptor. 
Nivolumab is EMA and FDA approved, whereas pembrolizumab is approved by the FDA 
when 50% or more of the tumor cells express programmed death ligand 1 (PD-L1) 
membrane staining of any intensity, as assessed by immunohistochemistry (IHC). Further 
immunotherapies are also in late-stage development and are discussed later in this 
review.7 In addition to antiangiogenic agents and checkpoint inhibitor immunotherapies, 
afatinib has also been approved by the FDA and has received a positive Committee for 
Medicinal Products for Human Use opinion for the treatment of squamous NSCLC 
progressing after platinum-based chemotherapy. Moreover, several targeted therapies are 
also available for patients with progressive disease and known oncogene addiction. These 
include alectinib (FDA approved) and ceritinib (FDA and EMA approved), both approved 
for use in ALK-positive patients who have progressed while receiving crizotinib or are 
intolerant to it. Osimertinib, an EGFR inhibitor, is EMA and FDA approved in T790M 
mutation–positive patients irrespective of prior treatment, although data in the first-line 
setting are limited. 
However, despite advances, many patients do not benefit from these therapies, and 
resistance will develop even in those who initially respond. Thus, there is a clear unmet 
need to improve the overall survival (OS) in most previously treated patients, while 
maintaining quality of life and improving tolerability of treatment. This need is particularly 
urgent in patients who do not have targetable oncogenic mutations or who fail to respond 
to targeted treatment. Emerging evidence that proangiogenesis factors have 
immunosuppressive activity has led investigators to evaluate the potentially synergistic 
combination of antiangiogenic agents and immunotherapy in the treatment of several 
cancers, including advanced NSCLC.These investigations are of particular interest in 
patients who are not expected to benefit from monotherapy with PD-1/PD-L1 inhibitors, 
such as those with PD-L1–negative tumors or, potentially, patients who are refractory to 
first-line therapy. 
In this narrative review, we provide an overview of treatment options for patients with 
advanced NSCLC, including the use of antiangiogenic or immunotherapeutic agents. We 
discuss the preclinical and clinical data exploring the potential and the challenges of 
combining antiangiogenesis with immunotherapy as a novel treatment option. 
Angiogenesis Inhibitors 
Angiogenesis is essential for primary tumor growth, and tumors are characterized by 
poorly organized and abnormal vessels with altered permeability. VEGF is the principal 
regulator of angiogenesis, stimulating proangiogenic signaling pathways by binding to its 
receptor, VEGFR2. Other key growth factors implicated in the regulation of angiogenesis 
include the platelet-derived growth factor and fibroblast growth factor families. 
The inhibition of angiogenesis signaling pathways is a well-established treatment modality 
in oncology. Angiogenesis inhibitors used to treat NSCLC fall into two categories: 
monoclonal antibodies targeting VEGF or VEGFR and small molecule TKIs. 
Antiangiogenic monoclonal antibodies that are currently approved for use in the treatment 
of NSCLC are bevacizumab and ramucirumab, targeting VEGF and VEGFR2, 
respectively. Bevacizumab, in addition to platinum-based chemotherapy, is EMA and FDA 
approved for the first-line treatment of advanced, metastatic, or recurrent NSCLC, 
excluding predominantly squamous cell histologic features. In a meta-analysis of 
randomized phase II/III trials in treatment-naive patients with advanced NSCLC, 
bevacizumab plus platinum-based chemotherapy significantly increased the OS versus 
chemotherapy alone (hazard ratio [HR] = 0.90, 95% confidence interval [CI]: 0.81–
0.99, p = 0.03). There was a significantly increased risk for several grade 3 or higher 
adverse events (AEs), although no unexpected patterns of toxicity emerged. For patients 
who have disease progression while or after receiving platinum-based chemotherapy, 
there are now options for antiangiogenic agents in combination with docetaxel. 
Ramucirumab in combination with docetaxel is EMA and FDA approved for the treatment 
of metastatic NSCLC. The phase III REVEL trial compared docetaxel plus ramucirumab 
with docetaxel plus placebo in patients with advanced NSCLC (any histologic type) who 
progressed after platinum doublet chemotherapy.11 Median OS in the docetaxel plus 
ramucirumab arm was 10.5 months versus 9.1 months in the docetaxel plus placebo arm 
(HR = 0.86, 95% CI: 0.75–0.98, p = 0.023). Overall, no significant increase in grade 3 or 
higher hemorrhage was observed in patients receiving ramucirumab, and most toxicities 
were manageable with appropriate dose reductions and supportive care. 
Until recently, the use of antiangiogenic TKI therapy in the treatment of NSCLC has been a 
decidedly unsuccessful strategy; numerous agents have failed to demonstrate meaningful 
improvements in OS, while also showing generally unfavorable toxicity profiles. However, 
nintedanib in combination with docetaxel was recently approved by the EMA for treatment 
of advanced, metastatic, or locally recurrent NSCLC of the adenocarcinoma tumor 
histologic type after first-line chemotherapy. Nintedanib is a novel triple angiokinase 
inhibitor that inhibits the VEGF, platelet-derived growth factor, and fibroblast growth factor 
signaling pathways In a phase III trial (LUME-Lung 1), nintedanib in combination with 
docetaxel demonstrated clinically meaningful benefits in patients who progressed after 
first-line treatment with chemotherapy. The primary end point was progression-free 
survival (PFS), with OS being the key secondary end point, in predefined subgroups in a 
stepwise order. In the first predefined population of patients with the adenocarcinoma 
histologic type who progressed within 9 months after the start of first-line treatment, the 
median OS was significantly improved in the docetaxel plus nintedanib group (10.9 months 
versus 7.9 months; HR = 0.75, 95% CI: 0.60–0.92, p = 0.0073). Similarly, significant 
improvements in median OS were obtained in the second predefined population of all 
patients with the adenocarcinoma histologic type (12.6 months in the docetaxel plus 
nintedanib group versus 10.3 months; HR = 0.83, 95% CI: 0.70–0.99, p = 0.0359). An 
exploratory analysis was also carried out in patients with adenocarcinoma who were 
refractory to first-line treatment (progressive disease as best response achieved). The 
median OS was longer with docetaxel plus nintedanib than with docetaxel plus placebo 
(9.8 months versus 6.3 months; HR = 0.62, 95% CI: 0.41–0.94, p = 0.0246). Although 
these efficacy results represent clinically meaningful gains for patients, it is worth noting 
that mutational analysis of the adenocarcinoma histologic type was lacking in this clinical 
trial. At the time of initiation of the LUME-Lung 1 study, EGFR biomarker testing was not 
standard clinical practice but analysis of the cohort for EGFR mutations was available for 
19.4% of the population of patients with adenocarcinoma (n = 128); of these patients, only 
16 (12.5%) were EGFR mutation–positive, with five and 11 EGFR mutation–positive 
tumors in the nintedanib and placebo arms, respectively (Boehringer Ingelheim, 
unpublished data, 2014). 
The LUME-Lung 2 study investigated nintedanib in combination with pemetrexed versus 
placebo-pemetrexed for the treatment of patients with advanced or recurrent 
nonsquamous NSCLC who had relapsed or failed one prior line of chemotherapy. 
Pemetrexed is widely used as a second-line agent for the treatment of nonsquamous 
NSCLC, and the results showed a significant improvement in independent centrally 
reviewed PFS with nintedanib/pemetrexed over placebo/pemetrexed (median 4.4 months 
versus 3.6 months; HR = 0.83, 95% CI: 0.70–0.99, p = 0.0435) at the time of the final 
analysis. On the basis of a preplanned investigator-assessed futility analysis, LUME-Lung 
2 recruitment was stopped prematurely, but combining nintedanib with pemetrexed 
significantly prolonged PFS in patients with advanced nonsquamous NSCLC after first-line 
chemotherapy, with a manageable safety profile. 
The general safety profile of nintedanib in combination with docetaxel was as expected. 
Gastrointestinal AEs and increased liver enzyme levels were the most common AEs, and 
there was a low incidence of AEs typically associated with antiangiogenic agents. These 
were manageable by application of standard oncological principles of judicious dose 
reductions and symptomatic treatment. Efficacy results from key phase III trials of 
angiogenesis inhibitors in NSCLC are reviewed in Table 1. 
 
Table 1. 
Efficacy Results from Phase III Trials of Angiogenesis Inhibitors in NSCLC 
 
Study ClinicalTrials.
gov Identifier 
Patients Compounds 
(Dose) 
Median 
OS, mo 
(95% 
CI) 
Median 
PFS, mo 
(95% CI) 
ORR 
ECOG45
99 
NCT0002106
0 
Stage IIIB/IV 
nonsquamous 
NSCLC (N = 
878) 
Paclitaxel + 
carboplatin 
vs. 
paclitaxel + 
carboplatin + 
bevacizumab 
10.3 
(NR) vs. 
12.3 
(NR) 
HR = 
0.79 
(0.67–
0.92), p 
= 0.003 
4.5 (NR) 
vs. 6.2 
(NR) 
HR = 
0.66 
(0.57–
0.77), p 
< 0.001 
15% vs. 
35%, p < 
0.001 
BEYOND NCT0136401
2 
Chinese 
patients with 
stage IIIB/IV 
nonsquamous 
NSCLC (N = 
276) 
Paclitaxel + 
carboplatin 
vs. 
paclitaxel + 
carboplatin + 
bevacizumab 
17.7 
(NR) vs. 
24.3 
(NR) 
HR = 
0.68 
(0.50–
0.93), 
p = 
0.0154 
6.5 (NR) 
vs. 9.2 
(NR) 
HR = 
0.40 
(0.29–
0.54), p 
< 0.01 
25% vs. 
54%, p < 
0.001 
AVAiL NCT0080692
3 
Stage IIIB/IV 
nonsquamous 
NSCLC (N = 
1043) 
Cisplatin + 
gemcitabine + 
bevacizumab 
(7.5 mg/kg or 
15 mg/kg) vs. 
placebo 
13.6 
(11.8–
15.8) 
and 13.4 
(11.1–
15.1) vs. 
13.1 
(11.8–
15.2) 
HR = 
0.93 
(0.78–
1.11), p 
= 0.42; 
and 
HR = 1.
03 
(0.86–
1.23), p 
= 0.761 
6.7 (NR) 
and 6.5 
(NR) vs. 
6.1 (NR) 
HR = 
0.75 
(0.64–
0.87), p 
= 
0.0003; 
and 
HR = 0.8
5 (0.73–
1.00), p 
= 0.0456 
38% and 
35% vs. 
22%, p ≤ 
0.0001 
and p = 0.00
02 
REVEL NCT0116897
3 
Stage IV 
squamous or 
nonsquamous 
NSCLC 
Docetaxel + 
ramucirumab 
vs. 
docetaxel + 
10.5 
(IQR 
5.1–
21.2) vs. 
4.5 (IQR 
2.3–8.3) 
vs. 3.0 
(IQR 
23% vs. 
14%, p < 
0.0001 
Study ClinicalTrials.
gov Identifier 
Patients Compounds 
(Dose) 
Median 
OS, mo 
(95% 
CI) 
Median 
PFS, mo 
(95% CI) 
ORR 
progressed 
after first-line 
chemotherapy 
(N = 1253) 
placebo 9.1 (IQR 
4.2–
18.0) 
HR = 
0.86 
(0.75–
0.98), p 
= 0.023 
1.4–6.9) 
HR = 
0.76 
(0.68–
0.86), p 
< 0.0001 
LUME-
Lung 1 
NCT0080519
4 
Stage IIIB/IV 
NSCLC 
progressed 
after first-line 
chemotherapy 
(patients with 
adenocarcino
ma histologic 
type who 
progressed 
within 9 mo 
after start of 
first-line 
treatment [n = 
405]; 
all patients 
with 
adenocarcino
ma histologic 
type 
[N = 658]) 
Docetaxel + 
nintedanib vs. 
docetaxel + 
placebo 
(patients with 
adenocarcino
ma histologic 
type who 
progressed 
within 9 mo 
after start of 
first-line 
treatment/all 
patients with 
adenocarcino
ma histologic 
type) 
10.9 
(8.5–
12.6) vs. 
7.9 
(6.7–
9.1) 
HR = 
0.75 
(0.60–
0.92), p 
= 
0.0073/ 
12.6 
(10.6–
15.1) vs. 
10.3 
(8.6–
12.2) 
HR = 
0.83 
(0.70–
0.99), p 
= 
0.0359 
3.6 (2.8–
4.3) vs. 
1.5 (1.4–
2.6) 
HR = 
0.63 
(0.48–
0.83), p 
= 
0.0008/N
R 
HR = 
0.77 
(0.62–
0.96), p 
= 0.0193 
4.9% vs. 
1.5%, p = 
0.0393/ 
4.7% vs. 
3.6%, p = 
0.4770 
LUME-
Lung 2 
NCT0080681
9 
Stage IIIB/IV 
nonsquamous 
NSCLC that 
progressed 
after first-line 
chemotherapy 
(N = 713) 
Nintedanib + 
pemetrexed 
vs. placebo + 
pemetrexed 
12.2 vs. 
12.7 
HR = 
1.03 
(0.85–
1.24), p 
= 
0.7921 
4.4 vs. 
3.6 
HR = 
0.83 
(0.70–
0.99), p 
= 0.0435 
9.1% vs. 
8.3%, NR 
OS, overall survival; CI, confidence interval; PFS, progression-free survival; ORR, objective 
response rate; NR, not reported; HR, hazard ratio, IQR, interquartile range. 
a 
Limited study data are currently available as a result of termination of the study on the basis of a 
preplanned futility analysis of investigator-reviewed PFS. Retrospective analysis showed that if the 
futility analysis had been conducted at a different time point or used centrally reviewed data, 
termination might not have been recommended. 
Immune Checkpoint Inhibitors 
In recent years, immunotherapies targeting the T-cell immune checkpoint receptor PD-1, 
or its ligand PD-L1 and cytotoxic T lymphocyte-associated protein 4 (CTLA-4), have 
brought significant improvements in some cancer outcomes. The rationale for the utility of 
immune checkpoint receptor therapy can be summarized as follows: the PD-1 pathway is 
a T-cell–inhibitory pathway that is induced by binding of the PD-1 receptor on the T-cell 
plasma membrane to PD-L1 on the tumor. Tumor cells have hijacked this pathway by 
upregulating PD-L1 expression, thereby preventing T-cell–mediated destruction. Thus, a 
PD-1/PD-L1 antagonistic antibody would allow antitumor T cells to be fully activated and 
generate tumor cell killing. Likewise, the binding of CTLA-4 on activated T cells to the 
B7 ligand on antigen-presenting dendritic cells results in reduction of the duration and 
magnitude of functional T-cell activation. Antagonistic anti–CTLA-4 antibodies blocking the 
CTLA-4–B7 interaction can relieve this inhibitory signal and enhance T-cell activity. 
In a rapidly evolving area, two PD-1 inhibitors are currently approved for the treatment of 
NSCLC: nivolumab and pembrolizumab (September 2016). Nivolumab is a fully human 
immunoglobulin G4 (IgG4) anti–PD-1 monoclonal antibody that is EMA and FDA approved 
for use in patients with metastatic NSCLC and progression during or after platinum-based 
chemotherapy. In two phase III trials, one in patients with the squamous histologic type 
(Checkmate 017) and the other with the nonsquamous histologic type (Checkmate 057), a 
reduction in the risk for death was demonstrated with nivolumab versus with docetaxel in 
previously treated patients. In Checkmate 017, the median OS was significantly longer with 
nivolumab than with docetaxel (9.2 months versus 6.0 months; HR = 0.59, 95% CI: 0.44–
0.79, p < 0.001). In Checkmate 057, the median OS was 12.2 months with nivolumab 
compared with 9.4 months with docetaxel (HR = 0.73, 95% CI: 0.59–0.89, p = 0.002). 9 In 
Checkmate 017, there was also significant improvement in PFS with nivolumab versus 
with docetaxel (3.5 months versus 2.8 months; HR = 0.62, 95% CI: 0.47–0.81, p < 0.001). 
PD-L1 expression was not predictive or prognostic in patients with the 
squamous histologic type. In contrast, in Checkmate 057 (nonsquamous histologic type), 
there was no PFS benefit with nivolumab versus with docetaxel (median PFS 2.3 months 
versus 4.2 months; HR = 0.92, 95% CI: 0.77–1.11, p = 0.39). However, at the interim 
analysis, there appeared to be a strong predictive association between increasing extent 
of PD-L1 expression and improved clinical outcome, for all efficacy outcomes, with 
nivolumab versus with docetaxel. In both trials, fewer grade 3 or higher treatment-related 
AEs (TRAEs) were reported in the nivolumab group than in the docetaxel group 
(Checkmate 017, 7% versus 55%; Checkmate 057, 10% versus 54%, respectively). 
Pembrolizumab is a humanized IgG4 anti–PD-1 monoclonal antibody that has been 
approved by the FDA and EMA for the treatment of patients with metastatic NSCLC whose 
tumors express PD-L1 and who have disease progression during or after platinum-based 
chemotherapy. In a phase II/III trial (KEYNOTE-010), patients with previously treated 
NSCLC with PD-L1 expression in 1% or more of tumor cells (centrally assessed with the 
Dako IHC assay [Dako, Carpenteria, CA] using murine 22C3 antihuman PD-L1 antibody 
[Merck, Kenilworth, NJ]) were randomly assigned to receive pembrolizumab, 2 mg/kg, 
pembrolizumab, 10 mg/kg, or docetaxel, 75 mg/m2. OS was significantly longer for 
pembrolizumab, 2 mg/kg, (10.4 months) versus for docetaxel (8.5 months; HR = 0.71, 95% 
CI: 0.58–0.88, p = 0.0008) and for pembrolizumab, 10 mg/kg, (12.7 months) versus 
docetaxel (HR = 0.61, 95% CI: 0.49–0.75, p < 0.0001), whereas PFS benefits were only 
significantly improved with pembrolizumab in patients with 50% or more of tumor cells 
expressing PD-L1. Further approvals in this second-line indication may occur in patients 
expressing PD-L1 at levels in 1% or more of tumor cells, and it is also being considered for 
first-line treatment in patients with higher levels of PD-L1 expression. Grade 3 to 5 TRAEs 
were less common with pembrolizumab than with docetaxel (13% in patients given 
pembrolizumab, 2 mg/kg, 16% in those given pembrolizumab, 10 mg/kg, and 35% in those 
given docetaxel), and the frequency of immune-related AEs was manageable (1%–5%). 
Monoclonal antibodies targeting PD-L1 are also in advanced clinical development. 
Atezolizumab, a humanized IgG engineered for low FcγR affinity, has been granted 
breakthrough therapy designation by the FDA on the basis of preliminary phase I efficacy 
results in previously treated patients with advanced NSCLC. Further support for this 
therapy stems from the results of the phase II POPLAR trial, also in patients with NSCLC 
who had progressed while receiving postplatinum chemotherapy. OS in the intention-to-
treat population, the primary end point, was 12.6 months with atezolizumab arm versus 9.7 
months with docetaxel (HR = 0.73, 95% CI: 0.53–0.99, p = 0.04). There was an 
association between increasing improvements in OS and increasing PD-L1 expression; 
PD-L1 expression was assessed by IHC both on tumor cells (percentage of total tumor 
cells grouped as less than 1%, 1% to <5%, ≥5% to <50%, or ≥50%) and on tumor-
infiltrating immune cells (percentage of tumor area grouped as <1%, ≥1% to <5%, ≥5% to 
<10%, or ≥10%). Atezolizumab was well tolerated, with 11% of patients experiencing 
grade 3 to 4 TRAEs versus 39% with docetaxel. Several phase III studies with 
atezolizumab are ongoing in patients with nonsquamous NSCLC, and the treatment looks 
likely to gain regulatory approval in NSCLC, pending favorable phase III data. Further 
investigational checkpoint inhibitors undergoing phase III trials in NSCLC include the 
human PD-L1 monoclonal antibodies, durvalumab (IgG4) and avelumab (IgG1). Efficacy 
results from phase II/III trials of PD-1/PD-L1 inhibitors in NSCLC are summarized 
in Table 2. With anti–PD-1 and anti–PD-L1 therapies, immune-related AEs, including 
pneumonitis, are infrequent and of low severity, but grade 3 to 4 drug-related immune 
toxicities that require early diagnosis and rapid medical management can develop in a 
small percentage of patients. 
 
Table 2. 
Efficacy Results from Phase II/III Trials of Immune Checkpoint Inhibitors in NSCLC 
 
Study ClinicalTrials.
gov identifier 
Patients Compounds 
(Dose) 
Median OS, 
mo (95% CI) 
Median PFS, 
mo (95% CI) 
ORR 
(95% 
CI) 
CheckMa
te-017 
NCT0164200
4 
Stage 
IIIB/IV, 
previously 
treated 
squamous 
NSCLC 
(n = 272) 
Nivolumab 
(3 mg/kg) vs. 
docetaxel 
(75 mg/m2) 
9.2 (7.3–13.3) 
vs. 6.0 (5.1–
7.3) 
HR = 0.59 
(0.44–
0.79), p < 0.0
01 
3.5 (2.1–4.9) 
vs. 2.8 (2.1–
3.5) 
HR = 0.62 
(0.47–
0.81), p < 0.
001 
20% 
(14–
28) vs. 
9% (5–
15), p 
= 0.008 
CheckMa
te-057 
NCT0167386
7 
Stage 
IIIB/IV, 
previously 
treated 
nonsquamo
us NSCLC 
(n = 582) 
Nivolumab 
(3 mg/kg) vs. 
docetaxel 
(75 mg/m2) 
12.2 (9.7–
15.0) vs. 9.4 
(8.1–10.7) 
HR = 0.73 
(0.59–
0.89), p = 0.0
02 
2.3 (2.2–3.3) 
vs. 4.2 (3.5–
4.9) 
HR = 0.92 
(0.77–
1.11), p = 0.
39 
19% 
(15–
24) vs. 
12% 
(9–
17), p 
= 0.02 
KEYNOT
E-010 
NCT0190565
7 
Stage 
IIIB/IV, 
previously 
treated 
nonsquamo
us or 
squamous 
NSCLC 
(n = 1034)a 
Pembrolizu
mab (2 
mg/kg and 
10 mg/kg) 
vs. 
docetaxel 
(75 mg/m2) 
10.4 (9.4–
11.9) and 
12.7 (10.0–
17.3) vs. 8.5 
(7.5–9.8) 
HR = 0.71 
(0.58–
0.88), p = 0.0
008 and 
HR = 0.61 
(0.49–
0.75), p < 
0.0001b 
3.9 (3.1–4.1) 
and 4.0 
(2.7–4.3) vs. 
4.0 (3.1–4.2) 
HR = 0.88 
(0.74–
1.05), p = 0.
07 and HR = 
0.79 (0.66–
0.94), p = 
0.004b 
18% 
(NR) 
and 
18% 
(NR) 
vs. 9% 
(NR), p
 = 
0.0005 
and p = 
0.0002b 
POPLAR NCT0190399
3 
Stage 
IIIB/IV, 
previously 
Atezolizuma
b (1200 mg 
fixed dose) 
12.6 (9.7–
16.4) vs. 9.7 
(8.6–12.0)d 
7.8 (NR) vs. 
3.9 (NR) 
HR = 0.60 
17% 
(11–
23.8) 
Study ClinicalTrials.
gov identifier 
Patients Compounds 
(Dose) 
Median OS, 
mo (95% CI) 
Median PFS, 
mo (95% CI) 
ORR 
(95% 
CI) 
treated 
nonsquamo
us or 
squamous 
NSCLC 
(n = 287)c 
vs. 
docetaxel 
(75 mg/m2) 
HR = 0.73 
(0.53–
0.99), p = 0.0
4 
(0.31–1.16) vs. 
15% 
(9.3–
21.4) 
OS, overall survival; CI, confidence interval; PFS, progression-free survival; ORR, objective 
response rate; HR, hazard ratio; NR, not reported; PD-L1, programmed death ligand 1. 
a 
This was a randomized, open-label phase II/III study. 
b 
Results are shown for the total analysis population (patients with PD-L1 expression of at least 1%). 
For the subgroup of patients with PD-L1 expression on at least 50% of tumor cells, please see main 
text. 
c 
Randomized, open-label phase II study. 
d 
PFS was reported only in the subgroup showing the highest expression of PD-L1 (≥50%). 
 
Synergistic Combination of Antiangiogenesis and Immunotherapy 
Current Hypotheses and Preclinical Rationale 
There is a growing body of evidence describing a complex relationship between 
angiogenesis and the immune system. It is also becoming apparent that antiangiogenic 
agents can stimulate the immune system, and it has been suggested that 
immunotherapies can also be antiangiogenic. This suggests that when combined, these 
two types of therapies could operate synergistically to target tumors (Fig. 1). Moreover, 
evidence indicates that the potential of such a combination regimen may be realized 
without a substantial increase in AEs.  The rationale for the approach and the current 
preclinical evidence are discussed in more detail in the following paragraphs. 
 
 
 
 
Figure 1. 
Combined inhibition of tumor angiogenesis and the immune checkpoint, programmed cell death 
protein 1 (PD-1). Abbreviations: Arg1, arginase 1; CD4, cluster of differentiation 4; CD8, cluster of 
differentiation 8; iDC, immature dendritic cell; IDO, indoleamine 2, 3-dioxygenase; IL-10, interleukin-
10; iNOS, inducible nitric oxide synthase; MDSC, myeloid-derived suppressor cell; NK, natural killer; 
PD-L1, programmed death ligand 1; PGE2, prostaglandin E2; TAM, Tyro3 Axl and Mer; R-NOS, 
reactive nitrogen oxide species; TGFβ, transforming growth factor β; Treg, T-regulatory cell; VEGF, 
vascular endothelial growth factor. 
Adapted with permission from Metpally RPR, et al. 
 
 
 
Over the past 20 years, evidence has accumulated that VEGF not only promotes 
angiogenesis but also acts as a key mediator of the immunosuppressive microenvironment 
that enables tumor cells to evade immunosurveillance.  VEGF signaling has been shown to 
attenuate the antitumor response through multiple mechanisms that can be divided into 
two modes of action. First, VEGF influences lymphocyte trafficking across endothelia to 
the tumor by inhibiting lymphocyte adhesion to activated endothelial cells and through an 
association with defects in endothelial intercellular adhesion molecule-1 and vascular cell 
adhesion molecule-1 clustering at the endothelial cell surface, thereby blocking T-cell 
infiltration into tumors, and by prevention of T-cell mobilization and trafficking into the 
tumor through its effect on the Fas ligand. Second, VEGF has a systemic effect on 
immune-regulatory cell function through multiple mechanisms, including the following: 
induction and proliferation of inhibitory immune cell subsets, such as T-regulatory cells 
(Tregs) and myeloid-derived suppressor cells (MDSCs); suppression of dendritic cell 
maturation; and inhibition of T-cell development from hematopoietic progenitor cells. 
Given the immunosuppressive role of VEGF and angiogenesis within tumors, it is not 
surprising that there is evidence that antiangiogenic agents stimulate the immune 
response and enhance the efficacy of immunotherapies. The multitarget TKI sunitinib 
decreased PD-1 expression in tumor-infiltrating T cells in advanced tumor–bearing mice 
and significantly increased the infiltration of CD8-positive and CD4-positive T cells into the 
tumor. Moreover, it reduced the number of Tregs and MDSCs in addition to impairing the 
suppressive function of MDSCs. In patients with renal cell carcinoma (RCC), sunitinib also 
decreased Treg and MDSC accumulation. Likewise, cabozantinib (a TKI inhibiting 
VEGFR2 among other targets), alone or in combination with MVA/rF-CEA/TRICOM (an 
anticancer vaccine with immune-stimulatory properties), reduced the number of Tregs and 
MDSCs in mice although significantly increasing the CD4-positive and CD8-positive T-cell 
infiltration. One reason for the increase seen in immune cell infiltration into tumors is 
thought to be the effect of antiangiogenic agents on tumor perfusion. Antiangiogenic 
agents can reduce tumor compactness, which is thought to relieve pressure on existing 
blood vessels and despite reduced tumor vasculature, result in both improved perfusion 
and oxygenation of the tumor microenvironment. 
The potential for increased efficacy by combining an antiangiogenic agent and 
immunotherapy is supported by preclinical evidence across several tumor types. In two 
in vivo cancer models, B16F10 melanoma and CT26 colon carcinoma cells, VEGF 
inhibition was achieved through systemic expression of a chimeric VEGFR that binds 
VEGF and blocks its function. When VEGF inhibition combined with granulocyte-
macrophage colony-stimulating factor–secreting tumor cell immunotherapy, the survival of 
the animals was significantly increased. Similarly, coadministering cabozantinib with 
MVA/rF-CEA/TRICOM significantly reduced the growth of MC38-CEA cancer cells in an 
in vivo model, compared with in the control of MVA/rF-CEA/TRICOM alone, and it resulted 
in durable regression of the tumors. In three different in vivo NSCLC models, combining 
immunotherapy (adoptive cellular immunotherapy using cytokine-induced killer [CIK] cell 
transfer) and inhibition of angiogenesis (with rh-endostatin) significantly inhibited the 
growth of the tumor, whereas neither treatment alone had a significant effect. Likewise, 
combined CIK cell therapy and bevacizumab in an in vivo lung adenocarcinoma model 
synergistically inhibited the growth of the tumors. There was increased infiltration of CIK 
cells into the tumor versus with other treatments. In a model of colon adenocarcinoma, 
simultaneous inhibition of PD-1 and VEGFR2 with monoclonal antibodies also inhibited 
tumor growth significantly compared with monotherapy treatments, but without inducing 
overt toxicity. This evidence has led to clinical investigations exploring the potential of 
combined antiangiogenesis and immunotherapy for the treatment of NSCLC. In addition, 
given the favorable toxicity profiles of both classes of agents, it was anticipated that this 
novel therapy combination would be well tolerated. 
Despite the potential efficacy benefits, combination therapy with an antiangiogenic agent 
and immunotherapy is not without challenges. One of the most pressing factors to be 
addressed in the future will be the identification of which patients might gain the most 
benefit from this novel combination, necessitating robust biomarkers to aid selection of 
these patients. This combination approach might benefit patients with poor prognosis, 
such as those not expected to benefit from checkpoint inhibitor monotherapy, including 
patients who are refractory to first-line therapy or who have PD-L1–negative tumors. In 
addition to the challenge of patient selection, the optimal sequence and the timing for each 
combination has to be determined, and for some this will be crucial. The dose of each 
agent may also be important, as it has been shown that high doses of antiangiogenic 
agents can have inferior immune-stimulating effects when combined with immunotherapy. 
Clinical Data 
Multiple trials are currently investigating combinations of angiogenesis inhibitors and 
immunotherapies in a range of cancers. These trials are supported by preliminary phase I 
data evaluating the efficacy and safety of these novel therapy combinations in 
NSCLC, gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, urothelial 
carcinoma, metastatic colorectal cancer (mCRC), and metastatic RCC 
(mRCC). Preliminary results are described in the paragraphs that follow, 
and Table 3 provides information about ongoing phase I trials assessing the combination 
of bevacizumab, ramucirumab, or nintedanib plus immune checkpoint antibodies in 
patients with advanced NSCLC. 
 
 
Table 3. 
Phase I Trials Evaluating the Combination of Antiangiogenic Agents and Immune Checkpoint 
Inhibitors in NSCLC 
Relevant 
Compou
nd(s) 
Study Title ClinicalTri
als.gov 
Identifier 
Estim
ated 
Enroll
ment 
(Total 
Study
) 
Primary 
End 
Points 
Relevant 
Regimens 
(Immunoth
erapy + 
Angiogene
sis 
Inhibitor in 
NSCLC) 
Relevant 
Patient 
Population 
Estim
ated 
Compl
etion 
Date 
Bevacizu
mab, 
nivoluma
b, 
ipilimum
ab 
A Multi-arm 
Phase I 
Safety Study 
of Nivolumab 
in 
Combination 
with 
Gemcitabine/
Cisplatin, 
Pemetrexed/
Cisplatin, 
Carboplatin/
Paclitaxel, 
Bevacizumab 
Maintenance, 
Erlotinib, 
Ipilimumab or 
as 
Monotherapy 
in Subjects 
with Stage 
IIIB/IV 
NSCLC 
(CheckMate-
012) 
NCT0145
4102 
412 Safety 
and 
tolerability 
of 
nivolumab
 + 
chemothe
rapy 
Cohort D: 
nivolumab 
+ 
bevacizum
ab 
maintenan
ce 
Newly 
diagnosed 
and 
confirmed 
stage IIIB/IV 
NSCLC 
Nove
mber 
2017 
Bevacizu
mab, 
pembroli
zumab 
A Phase I/II 
Study of MK-
3475 
(SCH900475
) in 
Combination 
with 
Chemothera
py or 
Immunothera
py in Patients 
with Locally 
Advanced or 
Metastatic 
NSCLC 
NCT0203
9674 
308 Part I, all 
cohorts: 
the 
recomme
nded 
phase II 
dose for 
pembroliz
umab + 
chemothe
rapy or 
immunoth
erapy 
Part I, 
cohort B: 
pembrolizu
mab + 
paclitaxel 
+ 
carboplatin
 + 
bevacizum
ab 
Stage IIIb/IV 
NSCLC 
June 
2019 
Bevacizu
mab 
atezolizu
mab 
A Phase Ib 
Study of the 
Safety and 
Pharmacolog
y of 
MPDL3280A 
Administered 
NCT0163
3970 
225 Incidence 
of AEs; 
DLTs/MT
D 
Cohort A: 
atezolizum
ab + 
bevacizum
ab 
Cohort B: 
atezolizum
Locally 
advanced or 
metastatic 
solid tumors 
(including 
stage IIIB/IV, 
or recurrent 
Septe
mber 
2017 
Relevant 
Compou
nd(s) 
Study Title ClinicalTri
als.gov 
Identifier 
Estim
ated 
Enroll
ment 
(Total 
Study
) 
Primary 
End 
Points 
Relevant 
Regimens 
(Immunoth
erapy + 
Angiogene
sis 
Inhibitor in 
NSCLC) 
Relevant 
Patient 
Population 
Estim
ated 
Compl
etion 
Date 
with 
Bevacizumab 
and/or with 
Chemothera
py in Patients 
with 
Advanced 
Solid Tumors 
ab + 
bevacizum
ab + 
FOLFOX 
NSCLC) 
Ramucir
umab, 
pembroli
zumab 
Study of 
Ramuciruma
b Plus 
Pembrolizum
ab in 
Participants 
with Gastric 
or GEJ 
Adenocarcin
oma, NSCLC 
or 
Transitional 
Cell 
Carcinoma of 
the 
Urothelium 
NCT0244
3324 
92 DLTs Cohort 3: 
ramucirum
ab + 
pembrolizu
mab in 
NSCLC 
patients 
Locally 
advanced 
and 
unresectable 
or metastatic 
gastric or 
GEJ adenoc
arcinoma, 
NSCLC, or 
transitional 
cell 
carcinoma of 
the 
urothelium 
Febru
ary 
2017 
Nintedan
ib, 
pembroli
zumab 
A Phase Ib 
Trial of 
Pembrolizum
ab and 
Nintedanib 
(PEMBIB) in 
advanced 
NSCLC 
NCT0285
6425 
258 Part I: 
MTD of 
nintedanib
 + 
pembroliz
umab 
Part Ib: 
safety and 
tolerability 
of 
nintedanib
 + 
pembroliz
umab and 
to 
evaluate 
the first 
efficacy 
signals 
Nintedanib
 + 
pembrolizu
mab 
Part I: 
patients with 
any 
advanced 
solid tumors 
Part Ib, 
cohort 1: 
locally 
advanced, 
metastatic 
or locally 
recurrent 
NSCLC 
(adenocarcin
oma 
histologic 
type) 
Part Ib, 
cohort 2: 
locally 
advanced, 
metastatic or 
locally 
recurrent 
NSCLC 
(SCC 
histologic 
type) 
July 
2021 
Relevant 
Compou
nd(s) 
Study Title ClinicalTri
als.gov 
Identifier 
Estim
ated 
Enroll
ment 
(Total 
Study
) 
Primary 
End 
Points 
Relevant 
Regimens 
(Immunoth
erapy + 
Angiogene
sis 
Inhibitor in 
NSCLC) 
Relevant 
Patient 
Population 
Estim
ated 
Compl
etion 
Date 
Nintedan
ib, 
nivoluma
b 
A Phase Ib 
Trial 
Combining 
Nivolumab 
and 
Nintedanib in 
Second-Line 
NSCLC With 
An 
Expansion 
Cohort 
TBD 
(Boehring
er 
Ingelheim
, 
unpublish
ed data, 
2016) 
50 Part I: 
MTD of 
nintedanib
 + 
nivolumab 
Part Ib: 
safety and 
tolerability 
of 
nintedanib
 + 
nivolumab 
and to 
evaluate 
first signs 
of efficacy 
in second-
line 
NSCLC 
(adenocar
cinoma 
histologic 
type) 
Nintedanib
 + 
nivolumab 
Patients with 
advanced 
NSCLC 
(adenocarcin
oma 
histologic 
type) 
TBD 
 
AE, adverse event; DLT, dose-limiting toxicity; MTD, maximum tolerated dose; GEJ, 
gastroesophageal junction; FOLFOX, fluorouracil, folinic acid (leucovorin), and oxaliplatin; TBD, to 
be determined; SCC, squamous cell carcinoma. 
 
 
 
 
In patients with advanced NSCLC who did not progress while receiving first-line platinum-
based chemotherapy, the safety and efficacy of switching to nivolumab maintenance 
therapy, as monotherapy or combined with bevacizumab, was evaluated (NCT01454102). 
The nivolumab plus bevacizumab arm included only patients with the nonsquamous 
histologic type, whereas the nivolumab monotherapy arm included patients with both the 
squamous and nonsquamous histologic types. Median OS was not reached in either arm. 
In the nivolumab plus bevacizumab arm, median PFS was 37.1 weeks, whereas the 
median PFS was 16 weeks in patients with squamous cell carcinoma and 21.4 weeks in 
patients with nonsquamous cell carcinoma in the nivolumab monotherapy arm. The 
objective response rate (ORR) was similar between the nivolumab plus bevacizumab (8%) 
and nivolumab-alone (10%) arms. In addition, nivolumab plus bevacizumab demonstrated 
a tolerable safety profile, with a low frequency of grade 3 or higher TRAEs. In conclusion, 
switching to nivolumab plus bevacizumab demonstrated a PFS similar to that seen with 
agents approved for maintenance therapy after platinum-based chemotherapy in 
advanced NSCLC, with an acceptable side effect profile. 
The combination of ramucirumab and pembrolizumab is being evaluated in patients with 
advanced NSCLC, G/GEJ adenocarcinoma, or urothelial carcinoma who had progressed 
during prior systemic therapy (NCT02443324). Preliminary results from the dose-limiting 
toxicity (DLT) portion of the study show no unexpected safety concerns. No DLTs were 
reported in patients with NSCLC, and one was reported in a patient with G/GEJ 
adenocarcinoma. 
In patients with mCRC, the safety and efficacy of combined treatment with bevacizumab 
and the PD-L1 inhibitor atezolizumab was assessed as a combination in refractory 
patients, or in oxaliplatin-naïve patients in conjunction with FOLFOX (fluorouracil, folinic 
acid [leucovorin], and oxaliplatin), which is a standard-of-care chemotherapy regimen for 
mCRC. Preliminary results in refractory patients who were treated with atezolizumab and 
bevacizumab and had at least one tumor assessment demonstrated an unconfirmed ORR 
of 8%. In oxaliplatin-naive patients treated with atezolizumab plus bevacizumab and 
FOLFOX, the unconfirmed ORR in patients with at least one tumor assessment was 36%, 
and in first-line patients it was 44%. In patients treated with atezolizumab and 
bevacizumab, 7% of grade 3 or higher AEs were considered to be related to atezolizumab, 
compared with 20% in patients also treated with FOLFOX. Both combination treatments 
were well tolerated, and no unexpected AEs emerged. 
Several trials are also currently ongoing with antiangiogenic agents and checkpoint 
inhibitor immunotherapies in patients with mRCC, with preliminary results being available 
for three phase I trials. In patients with mRCC and at least one tumor assessment, 
combined treatment with atezolizumab and bevacizumab in the first-line achieved a 
preliminary ORR of 40% (three of four responses confirmed at the time of data cutoff) and 
was well tolerated, with no grade 3 or higher AEs being attributed to treatment with 
atezolizumab (NCT01633970). A dose escalation study that evaluated bevacizumab plus 
pembrolizumab in patients with mRCC who had progressed while receiving at least one 
systemic therapy reported no DLTs or serious AEs related to the study drugs at the doses 
investigated (NCT02348008). Lastly, the combination of nivolumab and either pazopanib 
or sunitinib (both antiangiogenic agents approved for use in mRCC) is being evaluated in 
patients with mRCC who have received at least one prior systemic therapy 
(NCT01472081). An ORR of 45% was demonstrated in the nivolumab plus pazopanib arm, 
compared with 52% in the nivolumab plus sunitinib arm (expanded to include first-line 
patients). Grade 3 or higher related AEs occurred in 73% and 60% of patients, 
respectively, and the safety profile was considered to be manageable. Several trials 
investigating other combinations of antiangiogenic agents and immunotherapies in RCC 
are currently 
ongoing: NCT02231749, NCT02210117, NCT02014636, NCT02133742, NCT01984242, N
CT02420821, and NCT02493751. In addition, trials combining nintedanib with nivolumab 
and pembrolizumab, respectively, are in preparation. The results of these, and ongoing 
trials in other tumor types, are eagerly awaited to better understand the potential of 
combining antiangiogenic agents and immunotherapies. 
Promising results have also been reported in a phase I advanced melanoma trial 
combining bevacizumab and the CTLA-4 checkpoint inhibitor ipilimumab. The combination 
of ipilimumab and bevacizumab yielded an ORR of 19.6% and a median OS of 25.1 
months in patients with metastatic melanoma, almost doubling the survival time obtained 
in previous studies for ipilimumab alone. Tumor biopsy revealed endothelial activation 
associated with qualitative increases in T-cell and myeloid/monocyte cell infiltration into 
tumor deposits. Further evidence for immunological changes resulting from the addition of 
bevacizumab was an increased number of circulating memory T cells in peripheral blood. 
Importantly, the combination of bevacizumab and ipilimumab was well tolerated, in 
contrast to the combination of ipilimumab and nivolumab. 
Conclusions 
Angiogenesis mediated by VEGF is essential for tumor growth and metastasis, and tumor 
angiogenesis pathways are established therapeutic targets in NSCLC. Angiogenesis 
inhibition in the treatment of NSCLC has utilized two main strategies: monoclonal 
antibodies targeting VEGF (bevacizumab) or VEGFR (ramucirumab) or the small molecule 
TKI that inhibits multiple angiogenic and proliferative pathways (nintedanib). In recent 
years, a better understanding of the role of the immune system in repressing tumor growth 
and the mechanisms by which tumors evade immunosurveillance has stimulated the 
clinical development of immune checkpoint inhibitors for the treatment of NSCLC. The 
plethora of phase III studies of PD-1 and PD-L1 inhibitors currently under way will surely 
lead to an expansion of the use of immunotherapy in the clinical management of NSCLC. 
Recent findings indicating an intertwined regulation of VEGF signaling and 
immunosuppression in the tumor microenvironment suggest that the combination of anti-
VEGF agents and immune checkpoint blockade could have synergistic antitumor activity, 
along with favorable tolerability. A number of phase I trials evaluating this novel therapy 
combination in patients with advanced NSCLC, and other solid tumors, are currently in 
progress. Existing data on such combinations are promising but preliminary, and many 
challenges remain to be overcome before the full potential of combined immunotherapy 
and antiangiogenesis treatment can be realized. 
Acknowledgments 
We thank all the members of the advisory board Second Expert Panel, which was held at 
the Post-WCLC 2015 Conference, in Dresden, Germany, on 4–5 November 2015, at 
which these topics were presented and discussed. We would like to acknowledge the 
contribution of Dr. Suresh Senan (VU University Medical Centre, Amsterdam, the 
Netherlands) and Dr. Alex Adjei (Roswell Park Cancer Institute, New York, NY). Nicola 
Davis, PhD, and Aurora O’Brate, PhD, of inVentiv Health (London, United Kingdom), 
provided medical writing assistance for this manuscript, funded by Boehringer Ingelheim. 
All the authors were members of an advisory board held at the Post–World 
Conference on Lung Cancer 2015 Conference (November 5, 2015; Dresden, 
Germany), which was funded by Boehringer Ingelheim. 
Disclosure: Dr. Manegold has received consultation fees and travel expenses from 
Boehringer Ingelheim. Dr. Dingemans has received fees for consultation or advisory 
boards from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novartis, Pfizer, and 
Roche. Dr. Gray has received a grant from AstraZeneca and fees from 
AstraZeneca, Boehringer Ingelheim, and Genentech. Dr. Nakagawa has received 
research funding from EPS Associated, Japan Clinical Research Operations, 
Oncotherapy Science, and Quintiles. Dr. Nakagawa has also received research 
funding and personal fees from Astellas, AstraZeneca, Boehringer Ingelheim, 
Chugai Pharmaceuticals, Daiichi Sankyo, Eisai, Eli Lilly Japan, Merck Sharp and 
Dohme, Novartis, Ono Pharmaceuticals, Takeda, and Taiho Pharmaceutical. Dr. 
Nicolson has received research funding, meeting sponsorship, advisory board fees 
and nonfinancial support from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-
Myers Squibb, GlaxoSmithKline, Merck Sharp and Dohme, Novartis, and Roche. 
Dr. Reck has received honoraria/consultancy fees from AstraZeneca, Boehringer 
Ingelheim, Celgene, Eli Lilly, Bristol-Myers Squibb, Merck Sharp and Dohme, 
Novartis, Pfizer, Roche, and Samsung. Dr. Wu has received speaker fees from 
AstraZeneca, Eli Lilly, Pfizer, Roche, and Sanofi. Dr. Brustugun has received a 
grant from Boehringer Ingelheim. Dr. Crinò has received personal fees from 
AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, and Pfizer. Dr. Felip has 
received lecture fees from AstraZeneca, Bristol-Myers Squibb, and Novartis and 
consulting or advisory fees from Boehringer Ingelheim, Eli Lilly, Merck Sharp and 
Dohme, Pfizer, and Roche. Dr. Fennell has received personal fees from Bayer, 
Bristol-Myers Squibb, Clovis Oncology, Eli Lilly, and Roche/Chuagi. Dr. Garrido has 
received personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers 
Squibb, Celgene, Merck Sharp and Dohme, Novartis, Pfizer, and Roche, as well as 
nonfinancial support from AstraZeneca, Bristol-Myers Squibb, and Roche. Dr. 
Huber has received personal fees from Ariad, AstraZeneca, Boehringer Ingelheim, 
Bristol-Myers Squibb, Clovis Oncology, Eli Lilly, Pfizer, Pierre Fabre, and Roche. 
Dr. Moniuszko has received a research grant from Berlin-Chemie/Menarini and 
honoraria from Berlin-Chemie/Menarini, Boehringer Ingelheim, and Takeda. Dr. 
Novello has received speaker honoraria from AstraZeneca, Boehringer Ingelheim, 
Eli Lilly, Merck Sharp and Dohme, and Roche, as well as nonfinancial support from 
Boehringer Ingelheim. Dr. Papotti has received a grant from Novartis and personal 
fees from AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Novartis, 
Pfizer, and Roche. Dr. Perol has received honoraria from AstraZeneca, Boehringer 
Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly, Novartis, Pfizer, and 
Roche. Dr. Yang has received personal fees from Astellas, AstraZeneca, 
Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly, Merck Sharp 
and Dohme, Merck Sorono, Merrimack, Novartis, Ono Pharmaceuticals, Pfizer, and 
Roche/Genentech/Chugai. Dr. Zandwijk has received personal fees from 
AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Roche. Dr. Vokes has received 
personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, Celgene, Eli Lilly, 
Genentech, Merck Sharp and Dohme, Synta, and VentiRx. The remaining authors 
declare no conflict of interest. 
 
